drugset / Trial / NCT00712803
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
RandomizedParallel-groupDouble-blindPrevention
Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a new dengue virus vaccine in healthy adults.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-09
- Completion
- 2009-09
Publications
- Background Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg. 2004 Dec;71(6):811-21.
- Background Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res. 2005 May;121(5):639-52.
- Background Guzman MG, Mune M, Kouri G. Dengue vaccine: priorities and progress. Expert Rev Anti Infect Ther. 2004 Dec;2(6):895-911. doi: 10.1586/14789072.2.6.895.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rDEN3-3'D4delta30 | Vaccine | 10 unknown | Subcutaneous |
| Subject | rDEN3-3'D4delta30 | Vaccine | 1000 unknown | Subcutaneous |
| Subject | rDEN3-3'D4delta30 | Vaccine | 100000 unknown | Subcutaneous |